About United Therapeutics Corporation
https://www.unither.comUnited Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally.
CEO
Martine A. Rothblatt
Compensation Summary
(Year 2024)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2009-09-23 | Forward | 2:1 |
ETFs Holding This Stock
Summary
Showing Top 3 of 545
Ratings Snapshot
Rating : A-
Most Recent Analyst Grades
UBS
Buy
HC Wainwright & Co.
Buy
Jefferies
Buy
RBC Capital
Outperform
Oppenheimer
Outperform
Cantor Fitzgerald
Overweight
Grade Summary
Showing Top 6 of 10
Price Target
Institutional Ownership
BLACKROCK INC.
Shares:5.47M
Value:$2.6B
BLACKROCK, INC.
Shares:5.35M
Value:$2.55B
VANGUARD GROUP INC
Shares:4.42M
Value:$2.1B
Summary
Showing Top 3 of 920
About United Therapeutics Corporation
https://www.unither.comUnited Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $799.5M ▲ | $310.1M ▼ | $338.7M ▲ | 42.36% ▲ | $7.73 ▲ | $462.9M ▲ |
| Q2-2025 | $798.6M ▲ | $346.5M ▲ | $309.5M ▼ | 38.76% ▼ | $6.86 ▼ | $436.8M ▲ |
| Q1-2025 | $794.4M ▲ | $319.1M ▲ | $322.2M ▲ | 40.56% ▼ | $7.18 ▲ | $382.8M ▼ |
| Q4-2024 | $735.9M ▼ | $302.3M ▼ | $301.3M ▼ | 40.94% ▼ | $6.74 ▼ | $424.1M ▲ |
| Q3-2024 | $748.9M | $322.7M | $309.1M | 41.27% | $6.93 | $417.8M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $2.77B ▼ | $7.35B ▼ | $760.9M ▲ | $6.59B ▼ |
| Q2-2025 | $3.05B ▼ | $7.91B ▲ | $734.4M ▼ | $7.17B ▲ |
| Q1-2025 | $3.32B ▲ | $7.74B ▲ | $936.7M ▲ | $6.81B ▲ |
| Q4-2024 | $3.27B ▼ | $7.36B ▲ | $920M ▼ | $6.44B ▲ |
| Q3-2024 | $3.33B | $7.12B | $1.02B | $6.1B |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $338.7M ▲ | $562.1M ▲ | $140.9M ▲ | $-956M ▼ | $-253M ▲ | $351.6M ▲ |
| Q2-2025 | $309.5M ▼ | $191.7M ▼ | $-299.9M ▼ | $-198.6M ▼ | $-306.8M ▼ | $129.5M ▼ |
| Q1-2025 | $322.2M ▲ | $461.2M ▲ | $-164.7M ▼ | $-93.8M ▼ | $202.7M ▲ | $386.3M ▲ |
| Q4-2024 | $301.3M ▼ | $341.2M ▼ | $-123.2M ▼ | $-74.7M ▼ | $143.3M ▼ | $254.5M ▼ |
| Q3-2024 | $309.1M | $377.2M | $-114.9M | $-64.1M | $198.2M | $300.7M |
Revenue by Products
| Product | Q4-2024 | Q1-2025 | Q2-2025 | Q3-2025 |
|---|---|---|---|---|
 Adcirca | $0 ▲ | $10.00M ▲ | $10.00M ▲ | $10.00M ▲ |
 Orenitram | $110.00M ▲ | $120.00M ▲ | $120.00M ▲ | $130.00M ▲ |
 Product and Service Other | $10.00M ▲ | $10.00M ▲ | $10.00M ▲ | $10.00M ▲ |
 Remodulin | $130.00M ▲ | $140.00M ▲ | $130.00M ▼ | $130.00M ▲ |
 Tyvaso | $420.00M ▲ | $470.00M ▲ | $470.00M ▲ | $480.00M ▲ |
 Unituxin | $70.00M ▲ | $60.00M ▼ | $60.00M ▲ | $50.00M ▼ |
Revenue by Geography
| Region | Q4-2024 | Q1-2025 | Q3-2025 | Q2-2025 |
|---|---|---|---|---|
 NonUS | $30.00M ▲ | $40.00M ▲ | $20.00M ▼ | $40.00M ▲ |
 UNITED STATES | $710.00M ▲ | $750.00M ▲ | $770.00M ▲ | $760.00M ▼ |
CEO
Martine A. Rothblatt
Compensation Summary
(Year 2024)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2009-09-23 | Forward | 2:1 |
ETFs Holding This Stock
Summary
Showing Top 3 of 545
Ratings Snapshot
Rating : A-
Most Recent Analyst Grades
UBS
Buy
HC Wainwright & Co.
Buy
Jefferies
Buy
RBC Capital
Outperform
Oppenheimer
Outperform
Cantor Fitzgerald
Overweight
Grade Summary
Showing Top 6 of 10
Price Target
Institutional Ownership
BLACKROCK INC.
Shares:5.47M
Value:$2.6B
BLACKROCK, INC.
Shares:5.35M
Value:$2.55B
VANGUARD GROUP INC
Shares:4.42M
Value:$2.1B
Summary
Showing Top 3 of 920